RTW Investments Reports 2.9% Stake in Apellis Pharmaceuticals, Inc. (APLS)

RTW Investments, LP and Dr. Roderick Wong have filed a Schedule 13G/A for Apellis Pharmaceuticals, Inc. (APLS), reporting a beneficial ownership of 3,685,045 shares of common stock. This position represents a 2.9% ownership stake based on 127,829,909 shares outstanding as of February 2026. The filing indicates an increase in holdings from a previous reported position of zero. RTW Investments, acting as an investment adviser to various funds, and Dr. Wong, as Managing Partner and Chief Investment Officer, share voting and dispositive power over the reported shares. The filing was made pursuant to Rule 13d-1(b), indicating the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. Consequently, as the ownership level has dropped below the 5% threshold, the reporting persons have indicated that they no longer hold a significant reportable stake under standard 13G requirements, though they are disclosing their current 2.9% position in this amendment.